Brexpiprazole as an adjunctive treatment in young adults with major depressive disorder who are in a school or work environment

BackgroundMajor depressive disorder (MDD) is a common, debilitating disorder with substantial socioeconomic burden. Many patients with MDD experience symptoms that impair functioning and productivity, often negatively affecting work or educational pursuits. This Phase 3b open-label study evaluated adjunctive brexpiprazole in young adults with MDD, who were in work or study.MethodsYoung patients (18–35 years) with MDD (inadequate responders to 1–3 antidepressant treatments [ADT] for their current episode) received brexpiprazole 1–3mg/day (target dose, 2mg/day) adjunctive to the same stable dose of ADT for 12 weeks.ResultsDepressive symptoms improved during treatment with adjunctive brexpiprazole (primary endpoint, least squares [LS] mean change from baseline in Montgomery-Åsberg Depression Rating Scale [MADRS] total score, −18.1 [p